title: Molecular pathways: turning proteasomal protein degradation into a unique treatment approach.
abstract: Cancer treatment regimens have evolved from single cytotoxic substances affecting all proliferative tissues toward antibodies and kinase inhibitors targeting tumor-specific pathways. Treatment efficacy and cancer survival have improved overall, and side effects have become less frequent. The ubiquitin-proteasome system-mediated proteasomal protein degradation is the most critical pathway to regulate the quantity of signal proteins involved in carcinogenesis and tumor progression. These processes are, as well as protein recycling, highly regulated and offer targets for biomarker and drug development. Unspecific proteasome inhibitors such as bortezomib and carfilzomib have shown clinical efficacy and are approved for clinical use. Inhibitors of more substrate-specific enzymes of degradation processes are being developed and are now in early clinical trials. The novel compounds focus on the degradation of key regulatory proteins such as p53, p27(Kip1), and ß-catenin, and inhibitors specific for growth factor receptor kinase turnover are in preclinical testing.
authors.affiliation: Authors' Affiliation: USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Sharon Carpenter Laboratory, Los Angeles, California.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Stintzing
authors.affiliation: Authors' Affiliation: USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Sharon Carpenter Laboratory, Los Angeles, California lenz@usc.edu.
authors.forename: Heinz-Josef
authors.initials: HJ
authors.lastname: Lenz
mesh_terms: D006801:Humans; D009363:Neoplasm Proteins / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry* / Q000378:metabolism; D061988:Proteasome Inhibitors / Q000627:therapeutic use*; D059748:Proteolysis; D015398:Signal Transduction / Q000187:drug effects*; D025801:Ubiquitin / Q000378:metabolism*
chemical_list: D009363:Neoplasm Proteins; D061988:Proteasome Inhibitors; D025801:Ubiquitin; D046988:Proteasome Endopeptidase Complex
references.citation: Nat Rev Drug Discov. 2003 Aug;2(8):611-2
references.pmid: 12908468
references.citation: BMC Cancer. 2012 Nov 21;12:541
references.pmid: 23171055
references.citation: Leukemia. 2007 Apr;21(4):838-42
references.pmid: 17268529
references.citation: Mol Cell Biol. 2013 Aug;33(16):3309-20
references.pmid: 23775119
references.citation: Trends Biochem Sci. 2010 Nov;35(11):634-42
references.pmid: 20541423
references.citation: Cell Mol Life Sci. 2013 Jun;70(12):2123-38
references.pmid: 23007842
references.citation: Proc Natl Acad Sci U S A. 1999 May 25;96(11):6273-8
references.pmid: 10339577
references.citation: EMBO J. 2007 Feb 21;26(4):976-86
references.pmid: 17290220
references.citation: F1000Prime Rep. 2013 Nov 01;5:45
references.pmid: 24273646
references.citation: J Mol Biol. 2013 Dec 13;425(24):4995-5008
references.pmid: 24095857
references.citation: Nature. 2002 Apr 11;416(6881):648-53
references.pmid: 11923872
references.citation: FASEB J. 2010 Apr;24(4):981-93
references.pmid: 19940261
references.citation: Cell. 2010 Feb 5;140(3):384-96
references.pmid: 20096447
references.citation: Clin Cancer Res. 2013 Apr 1;19(7):1784-94
references.pmid: 23403634
references.citation: Cancer Lett. 2011 Dec 22;312(2):209-18
references.pmid: 21937165
references.citation: Mol Cancer Ther. 2013 Apr;12(4):373-83
references.pmid: 23339190
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Expert Opin Ther Targets. 2013 Sep;17(9):1091-108
references.pmid: 23822887
references.citation: PLoS One. 2008 Jan 23;3(1):e1487
references.pmid: 18213395
references.citation: Cancer Biol Ther. 2012 Jul;13(9):804-11
references.pmid: 22669575
references.citation: Lancet. 2003 Jun 14;361(9374):2059-67
references.pmid: 12814730
references.citation: Annu Rev Genet. 2013;47:167-86
references.pmid: 24016193
references.citation: Blood Rev. 2013 Nov;27(6):297-304
references.pmid: 24183816
references.citation: BMC Cancer. 2012 Sep 19;12:415
references.pmid: 22992303
references.citation: Clin Cancer Res. 2014 Jan 15;20(2):289-95
references.pmid: 24270683
references.citation: Science. 2004 Feb 6;303(5659):844-8
references.pmid: 14704432
references.citation: Nature. 2010 Jan 7;463(7277):103-7
references.pmid: 20023629
references.citation: Biochim Biophys Acta. 2012 Oct;1823(10):1686-96
references.pmid: 22705350
references.citation: FEBS Lett. 2011 Sep 16;585(18):2853-60
references.pmid: 21605559
references.citation: Am J Clin Oncol. 2013 Jun;36(3):239-43
references.pmid: 22441342
references.citation: Mol Cancer Res. 2006 Oct;4(10):729-45
references.pmid: 17050667
references.citation: Int J Biochem Cell Biol. 2007;39(12):2173-82
references.pmid: 17855153
references.citation: J Biol Chem. 2013 Aug 9;288(32):23505-17
references.pmid: 23744067
references.citation: Clin Cancer Res. 2011 Oct 1;17(19):6313-21
references.pmid: 21831953
references.citation: EMBO J. 2013 Feb 20;32(4):552-65
references.pmid: 23314748
references.citation: Mol Cancer. 2009 Dec 03;8:115
references.pmid: 19958544
references.citation: Mol Cell Biol. 2011 May;31(10):2053-65
references.pmid: 21383061
references.citation: Cell Cycle. 2013 Sep 1;12(17):2733-7
references.pmid: 23966173
references.citation: Cancer Res. 2010 Nov 15;70(22):9265-76
references.pmid: 21045142
references.citation: Cancer Res. 2007 Oct 1;67(19):9006-12
references.pmid: 17909001
references.citation: Mol Cell. 2010 Jun 11;38(5):722-32
references.pmid: 20542004
references.citation: Cell. 1996 Jul 26;86(2):263-74
references.pmid: 8706131
references.citation: Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):433-8
references.pmid: 21729686
references.citation: Blood. 2010 Mar 18;115(11):2251-9
references.pmid: 20075161
references.citation: Chin J Cancer. 2012 Apr;31(4):169-77
references.pmid: 22200179
references.citation: Leuk Res. 2008 Nov;32(11):1751-5
references.pmid: 18485478
references.citation: Fam Cancer. 2012 Dec;11(4):661-5
references.pmid: 22829014
references.citation: Front Biosci (Landmark Ed). 2012 Jun 01;17:2197-212
references.pmid: 22652772
references.citation: J Clin Oncol. 2013 Mar 20;31(9):1231-8
references.pmid: 23358974
references.citation: Mol Cell. 2001 May;7(5):927-36
references.pmid: 11389840
references.citation: Mol Cell. 1998 Aug;2(2):233-9
references.pmid: 9734360
references.citation: Cancer Cell. 2012 Sep 11;22(3):345-58
references.pmid: 22975377
references.citation: Breast Cancer Res Treat. 2013 Jan;137(2):359-71
references.pmid: 23225169
references.citation: Leukemia. 2009 Mar;23(3):467-76
references.pmid: 19039324
references.citation: J Biol Chem. 2012 Aug 31;287(36):30701-10
references.pmid: 22730322
references.citation: Nature. 2009 Mar 26;458(7237):422-9
references.pmid: 19325621